

1642

PH#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant(s): Feige, et al.

Serial No.: 09/428,082

Filed: October 22, 1999

For: Modified Peptides as Therapeutic Agents

Docket No.: A-527



Group Art Unit No.: 1642

Examiner: S. Huff

RECEIVED

JAN 19 2001

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 form for consideration by the Examiner.

Applicants, by the undersigned attorney, certify that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Timothy J. Gaul
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date: January 11, 2001

Please send all future correspondence to:
U.S. Patent Operations/ TJG
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

January 11, 2001
Date

Christina A. Gutierrez
Signature